The risk of fetal malformations associated with maternal drug use depends on the properties of the drug and the time period of the fetus’s exposure. Exposure up to 32 days after conception can affect neural tube development and closure; exposure 21–56 days after conception may affect heart formation; and exposure during days 42–63 may influence development of the lip and palate. Craniofacial anomalies can also occur after the first trimester. In addition, neurobehavioral teratogenicity can result from exposure after the first trimester. The following review is organized by domain of reproductive toxicity, including structural malformations, growth retardation, perinatal toxicity, and adverse neurobehavioral sequelae. The current U.S. Food and Drug Administration (FDA) classification of teratogenicity is being revised to better address and inform clinicians about the risks of fetal exposure (10). Therefore, the FDA classification is not used in this review.
Although lithium is effective for only a subgroup of patients with bipolar disorder (11), it remains one of the mainstays for acute and maintenance treatment.
Shortly after lithium came into common use, concerns arose about an association between prenatal lithium exposure and congenital malformations. The Register of Lithium Babies (12), a voluntary physician-reporting database, noted a 400-fold higher rate of cardiovascular malformations, most notably Ebstein’s anomaly, in offspring exposed in utero, compared with the general population. This congenital anomaly, characterized by downward displacement of the tricuspid valve into the right ventricle and variable levels of right ventricular hypoplasia, occurs at a rate of 1:20,000 in the general population (13). Subsequent investigations identified a risk of Ebstein’s anomaly among offspring of lithium users of 1:1,000 (0.1%) to 2:1,000 (0.05%), or 20 to 40 times higher than the rate in the general population (14–16). Thus, the relative risk for Ebstein’s anomaly with prenatal lithium exposure is somewhat higher than in the general population, although the absolute risk remains small.
Intrauterine growth effects
Lithium-exposed infants were found to weigh significantly more than comparison subjects by a mean of 92 g (3475 g, compared with 3383 g) (15), even though lithium-treated women were more likely to smoke cigarettes, which typically decreases birth weight. The maternal lithium dose did not correlate with birth weight.
In a follow-up study of children included in the Register of Lithium Babies, 60 children exposed to lithium either during the first trimester or throughout pregnancy did not differ behaviorally from their nonexposed siblings (17). In another study (15), the attainment of major developmental milestones for 22 lithium-exposed subjects was similar to that for nonexposed comparison subjects.
The most common toxicity effect in offspring exposed to lithium during labor is the "floppy baby" syndrome, characterized by cyanosis and hypotonicity (18, 19). Cases of neonatal hypothyroidism and nephrogenic diabetes insipidus have also been described (20, 21). Close monitoring of lithium levels in the mother during labor is now routine.
Lithium has a relatively short half-life (8–10 hours) and produces substantial peak and trough serum levels. More frequent dosing (three to four times a day) allows patients to maintain therapeutic serum levels and avoid peaks, although it is unclear whether this technique benefits the fetus (22). Lithium serum levels, which may be affected by vomiting, sodium intake, and febrile illnesses, should be monitored closely (22). As pregnancy progresses, renal lithium excretion increases, generally necessitating an increase in dose (23). Lithium levels in umbilical cord blood have been found to be equivalent to maternal blood levels (23), and the concentration of the cation may be higher in amniotic fluid than in blood (24). The significance of this finding is unknown. Some experts advise decreasing the dose of lithium at the onset of labor to avoid toxicity associated with the rapid reduction of vascular volume at delivery (25). Vigilant monitoring of symptom and lithium serum levels is required to avoid relapse or toxicity during delivery and the immediate postpartum period (7, 16). Adequate hydration should be maintained, and use of intravenous fluids should be considered for patients in prolonged labor.
In the case of first-trimester exposure, anomalies can be identified with prenatal screening with a high-resolution ultrasound examination and fetal echocardiography at 16–18 weeks gestation (16, 26). This procedure aids parents in decisions regarding pregnancy termination and perinatal interventions after delivery.
A number of anticonvulsants, most notably sodium valproate and carbamazepine, have been used in the acute treatment of bipolar disorder. Some of these anticonvulsant agents represent more potent teratogenic risks than lithium. Exposure is associated with a twofold increase in the rate of malformations (27), which include neural tube defects (spina bifida, anencephaly), craniofacial anomalies, growth retardation, microcephaly, and heart defects (28). The "anticonvulsant face," characterized by mid-face hypoplasia, short nose with anteverted nostrils, and long upper lip, has been associated with both carbamazepine and valproate exposure (28). Teratogenic risk is higher with polytherapy than with monotherapy (29). Many experts recommend avoiding the combination of valproate and carbamazepine, particularly if there is a family history of neural tube defects (30). In contrast, lamotrigine, which was recently approved for maintenance treatment of bipolar disorder, appears to be associated with a lower rate of malformations overall and has emerged as a first-line treatment for women with epilepsy during their reproductive years (31). Nonetheless, the overall incidence of miscarriage or stillbirth is significantly higher in anticonvulsant-treated women with epilepsy, compared to unmedicated women with epilepsy (14% and 4%, respectively) (32).
Sodium valproate is considered a human teratogen. Use of this compound during the first trimester is associated with neural tube defect rates of about 5%–9% (33, 34). The effect of the drug on neural tube development is related to its use 17–30 days postconception, and risk is dose related (35, 36). The neural tube defect found in exposed infants is more likely to be lumbosacral rather than anencephalic, which suggests a drug effect on neural crest closure (34).
Intrauterine growth effects
Some researchers (10) have suggested that intrauterine growth retardation is part of the "fetal valproate syndrome" (36), but intrauterine growth retardation has not been found to be an invariable consequence of valproate use during pregnancy (10).
Mental retardation has been included in the "fetal valproate syndrome" (37), but the data to support its inclusion are not definitive.
Neonatal complications associated with valproate use near the time of delivery include heart rate decelerations (36) and withdrawal symptoms of irritability, jitteriness, feeding difficulties, and abnormal tone (34). Other complications among neonates include liver toxicity (38) and hypoglycemia (39). Reductions in neonatal fibrinogen levels have also been reported (40). It is noteworthy that the drug carries an FDA warning for use in children under the age of 2 years.
In treatment of women with bipolar disorder or epilepsy, some experts recommend that valproate be switched to another mood stabilizer before conception (41). Women with unplanned pregnancies may not find that they are pregnant until after the deleterious effects of exposure have occurred, thus obviating most of the benefit that could occur from switching medications. Valproate is concentrated in the fetal compartment (35), and its concentration is twofold higher in cord serum than in maternal serum (42). Single daily dosing may cause unpredictably high peak levels (30).
Valproate levels are affected by the presence of other antiepileptic drugs that increase the activity of metabolic enzymes. In pregnancy, glucuronidation is induced, potentially leading to lower serum valproate levels. Patients should be monitored closely to ensure therapeutic efficacy.
Folate supplementation during pregnancy reduces the risk of neural tube defects generally, but it has not been tested as prophylaxis in pregnant women undergoing anticonvulsant treatment. Some researchers have recommended a daily dose of 5 mg of folic acid before and during pregnancy or at least through the first trimester for all women taking antiepileptic drugs (43). The American Academy of Neurology has recommended a more conservative dose of 3–4 mg/day of folic acid but has stated that the optimal dose has yet to be established (41). The patient’s level of vitamin B12 should be measured before folate supplementation to assess for concurrent pernicious anemia, which can be masked with folate treatment.
Carbamazepine is also considered a human teratogen. In one prospective study of 35 women treated with carbamazepine during the first trimester (28), craniofacial defects (11%), fingernail hypoplasia (26%), and developmental delay (20%) were found in live-born offspring. The rate for neural tube defects in that report and others ranged between 0.5% and 1% (28, 44).
The teratogenic potential of carbamazepine is enhanced when it is given with other agents and in particular with valproate, perhaps because the concentration of toxic epoxide metabolites is increased (45). In theory, oxcarbazepine, which does not produce the epoxide metabolite, may be less teratogenic. However, studies have not been performed to confirm this speculation.
Intrauterine growth effects
Carbamazepine is associated with reductions in birth weight (of about 250 g) (46) and mean head circumference (standardized for gestational age and sex) (47).
No associations between carbamazepine and significant cognitive dysfunction have been detected in controlled studies (48).
In two case reports, carbamazepine was associated with transient hepatic toxicity (cholestatic hepatitis  and direct hyperbilirubinemia ) in neonates exposed to the drug during pregnancy. The hepatic dysfunction resolved after cessation of breast-feeding in both cases.
Most experts feel carbamazepine should be used during pregnancy only if other options are lacking. As with valproate, an unplanned pregnancy may not be confirmed until the woman is in the highest risk period for a teratogenic effect. For women who continue treatment, fetal serum levels of carbamazepine are 50%–80% of maternal levels (51). Some studies show that serum levels during pregnancy remain constant for the main compound and the epoxide metabolite, although not all reports concur (10). If possible, it is best to monitor unbound levels of the compound.
Women who are started on the drug after conception incur more risk of serious side effects (agranulocytosis, hepatic failure, and Stevens-Johnson syndrome) than individuals who are undergoing carbamazepine treatment at conception, since the risks are higher within the first 8 weeks after treatment is initiated (52).
Carbamazepine can cause fetal vitamin K deficiency. Since adequate levels of vitamin K are necessary for normal mid-facial growth and for the functioning of clotting factors, carbamazepine exposure in utero could increase the risk of neonatal bleeding and mid-facial abnormalities. Most experts recommend administering 20 mg/day of oral vitamin K in the last month of pregnancy in women taking carbamazepine (30, 41). Pediatricians should also administer 1 mg i.m. of vitamin K to neonates after in utero carbamazepine exposure.
Lamotrigine was recently approved as a maintenance therapy for bipolar disorder. Two studies have demonstrated an increased time to subsequent mood episodes in patients treated with lamotrigine (53, 54). The obstetrical outcome data contained in the Lamotrigine Pregnancy Registry maintained by GlaxoSmithKline (54) includes data from international registries and postmarketing surveillance. As of September 30, 2003, a total of 1,081 cases have been registered and 693 birth outcomes have been obtained. Nine major defects were identified in offspring of women treated with monotherapy (N=415), yielding an estimate of 2%, while the rate was 3.4% in the 278 women undergoing treatment with several anticonvulsants. These rates are similar to the general population rate for major malformations. These defects included one instance of anencephaly and two instances of ventral septal defects. Polytherapy that included valproic acid was associated with a higher rate of malformations—10.4% (7/67).
Intrauterine growth effects
The impact of lamotrigine on intrauterine growth has not been detailed.
A single follow-up of 23 infants demonstrated no alterations in development at 12 months of age (55).
Clinicians should be aware of reports of hepatotoxicity in adults taking lamotrigine and concerns about the development of lamotrigine-related skin rash in a fetus or neonate whose antigen characteristics are different from those of the mother. An additional concern is that lamotrigine is metabolized exclusively by means of glucuronidation, a metabolic process that is very immature in the fetus and neonate. Measurement of the clearance of lamotrigine in neonates over the first 72 hours of life demonstrated only a 25% decrease relative to umbilical cord blood concentrations (56).
The clearance of lamotrigine during pregnancy has generated attention secondary to its increased use and the characteristics of its metabolic pathway. Two studies have found a significant increase in the clearance rate during pregnancy (i.e., a decrease in serum concentration) (57, 58). It is noteworthy that the rate of clearance returned to preconception levels rapidly after delivery, indicating the need for careful dose management in the early postpartum period.
The utility of gabapentin for treatment of mania has not been established (59, 60) and is not discussed in this report. Selected newer anticonvulsants, including zonisamide and levetiracetam, are under investigation for use in the treatment of mania and depression.
First-Generation Antipsychotic Agents
One of the largest databases available is for the older, first-generation antipsychotic agents, although even this information is limited. Phenothiazines and butyrophenones have historically been used to treat hyperemesis gravidarum, nausea, and, less commonly, psychotic disorders in pregnant women. First-generation antipsychotic agents are often prescribed with anticholinergic agents such as benztropine mesylate. Risks associated with this adjunctive agent are covered in the section on ECT.
The best-studied phenothiazine is chlorpromazine, which was prescribed for hyperemesis gravidarum during the 1950s, usually in low doses (61, 62). In a case-control study of 315 exposed and 11,099 nonexposed women, investigators found a slightly higher rate of malformations (3.5% versus 1.6%) among exposed offspring (61). However, in a survey of more than 50,000 mother-child pairs that identified 142 first-trimester exposures and 284 total exposures to chlorpromazine, there was no elevation in the rate of physical malformations with chlorpromazine (62). The latter study also suggests that related compounds, including trifluoperazine, perphenazine, and prochlorperazine, are similarly not associated with higher-than-expected rates of malformations (62).
In one of the few studies to assess antipsychotic use in pregnant psychotic women, 52 women who took chlorpromazine throughout pregnancy were compared with 110 pregnant women with psychosis who were not exposed to chlorpromazine (63). The rates of malformations among offspring in the two groups were similar but approximately twice the rate in the general population. This finding suggests that the higher rate of anomalies may be influenced by the underlying illness. Genetic factors or behaviors such as smoking, substance abuse, and poor prenatal care may account for the higher rate of malformations.
A few case reports have suggested an association between haloperidol and limb reductions, but large case series have not supported this finding (64). A meta-analytic study of first-trimester exposure to low-potency neuroleptics found an increase of one case of malformation for every 250 pregnancies in which exposure occurred (26).
A withdrawal-emergent syndrome (irritability, tongue thrusting with feeding difficulty, abnormal hand posturing, and tremor of all extremities) lasting 6 months was described in an infant exposed to haloperidol during pregnancy (65). Extrapyramidal symptoms, including hypertonicity, tremors, motor restlessness, spasticity, and difficulty with feeding, have been found in infants exposed to chlorpromazine (66). Such symptoms have been reported to last up to 10 months, but most resolve within days. On the other hand, hypotonicity can occur in the neonate if the mother’s dose of chlorpromazine is high (67). Some of these complications may have been related to use of concomitant anticholinergic and antihistaminergic agents.
Investigations did not find diminished intelligence among 4-year-old progeny exposed to phenothiazines or butyrophenones (62). Children with and without histories of neuroleptic exposure showed no differences in behavioral functioning or IQ when followed up to 5 years of age (68).
First-generation antipsychotic agents continue to have a role in the acute treatment of mania during pregnancy (69). Some experts consider the risk associated with first-generation antipsychotic agents, which have been available for decades, to be less than the risk associated with selected mood stabilizers (26). Clinicians may elect to switch a patient’s medication from lithium or an anticonvulsant to a first-generation antipsychotic either for the entire pregnancy or for the first trimester. This strategy is particularly useful for patients who have benefited from mood stabilization with antipsychotic medications in the past. First-generation antipsychotic medications may also be a choice for women with bipolar disorder who elect to discontinue medication during pregnancy but begin to experience a recurrence of symptoms while pregnant.
Second-Generation Antipsychotic Agents
Several second-generation antipsychotics, including quetiapine and risperidone, are currently under review but have not been approved by the FDA for acute and maintenance treatment of bipolar disorder. Olanzapine recently received approval from the FDA for treatment of acute mania, but experience with this drug in pregnancy is limited.
Olanzapine was not associated with malformations in several case reports and series (70, 71).
No data exist on neonatal toxicity.
Data are limited, but olanzapine has been associated with weight gain, insulin resistance (72), gestational diabetes (73), and preeclampsia (73). Weight gain, blood sugar levels, and blood pressure should be monitored carefully in patients who are taking olanzapine.
The effects of calcium channel blockers, such as verapamil, in the treatment of bipolar disorder have been studied (74–76), although their efficacy remains unproven (77). Because verapamil is used to treat maternal hypertension and fetal arrhythmias, the effects on the fetus of exposure during the first trimester have been evaluated. In a controlled study, two of 66 subjects exposed to nifedipine or verapamil developed malformations, compared to none of a group of nonexposed comparison subjects, but the difference was not significant (p=0.27), and the study had sufficient power to rule out only a very large (fivefold) difference in risk (78). A higher rate of preterm delivery (28% versus 9% in the control group) (p=0.0003) was ascribed to maternal disease for which the drugs were prescribed. In two therapeutic trials of verapamil among hypertensive pregnant women, no adverse drug-related effects were observed among infants (79).
Benzodiazepines and Other Sedative Hypnotic Agents
Benzodiazepines are used commonly as adjunctive medications for mood stabilization or for anxiety, agitation, and sleep problems. The most commonly prescribed benzodiazepines for individuals with bipolar disorder are lorazepam and clonazepam.
There are no reports of malformations associated with lorazepam or clonazepam. The reproductive safety of the prototype drug in this class, diazepam, is controversial. Early reports described an increased risk of oral clefts after first-trimester exposure to drugs such as diazepam (80), but later studies have not supported this association (81, 82). A recent meta-analysis found an association between oral cleft and benzodiazepine use only among case-control studies (odds ratio=1.79, 95% confidence interval=1.13–2.82) but not in cohort studies (83). The difference in findings among studies is probably due to the greater sensitivity of case-control studies in analyzing events that are rare. Results from case-control studies of the relationship between benzodiazepine exposure and cleft lip or palate have suggested a risk rate of about 11:10,000 births, an increase of about 80% over the base risk rate of 6:10,000 births in the general population, but still a rate that yields rare events (83).
Although the risk of physical anomalies with benzodiazepines is not greatly elevated, it may be even less for the high-potency agents in this class. The high-potency compounds may also be preferable, since they have shorter half-lives, have less accumulation, and are less likely to cause sedation.
Sleep dysregulation may be a potent trigger for illness recurrence in bipolar disorder. This idea is supported by one study that found a high rate of manic relapse among fathers with bipolar disorder during the postpartum period (84). Benzodiazepines are useful for regulating sleep and may help in prophylaxis against postpartum recurrence of manic episodes.
Intrauterine growth retardation
Intrauterine growth retardation associated with diazepam use has been reported (85), but complications with lorazepam or clonazepam have not been described.
Acute side effects from benzodiazepines occur in association with therapy near term. Case reports have described impaired temperature regulation, apnea, lower Apgar scores at both 1 and 5 minutes, muscular hypotonia, and failure to feed (10).
Infants born to mothers who chronically used benzodiazepines may evidence withdrawal symptoms, including tremor, irritability, diarrhea, vomiting, vigorous sucking, and hypertonicity (10). In one small study of a series of infants whose mothers (N=39) had taken clonazepam (0.5–3.5 mg/day) for treatment of panic disorder during pregnancy, neonatal toxicity was not found (86).
Systematically derived data on the long-term neurobehavioral effects of benzodiazepine exposure are sparse. Motor and developmental delays have been reported, although these reports have been criticized for having significant ascertainment biases (87). Other investigators have found no association between benzodiazepine exposure and developmental delay (88).
When used in pregnant patients, ECT has relatively few side effects and may pose fewer risks than untreated mood episodes or pharmacotherapy with a teratogenic agent.
While there have been occasional reports of congenital malformations in offspring exposed to ECT in utero (89), neither the number nor the pattern of these findings implicates ECT as a causal factor.
Overall, reported complications of ECT during pregnancy are uncommon and transient (90). Barbiturates and atropine can reduce beat-to-beat variability in the fetal heart rate, and atropine can cause fetal tachycardia. The risk of fetal cardiac arrhythmias can be minimized by avoiding atropine, ensuring adequate oxygenation, avoiding excessive hyperventilation, and elevating the right hip. Fetal cardiac monitoring during ECT will allow for detection of arrhythmias and correction of any contributory problems.
Uterine smooth muscle does not routinely contract during a seizure. However, a few cases of uterine contractions have been observed after ECT (91). These contractions did not usually lead to premature labor (90). Patients who are malnourished or dehydrated may be more vulnerable to such contractions. For high-risk patients and/or for patients who cannot reliably recognize and articulate their bodily sensations, uterine tocodynamometry can be used to register uterine contractions.
Seizure threshold is decreased by estrogen and increased by progesterone. Changes in the ratio of estrogen to progesterone during pregnancy can theoretically alter seizure threshold, thereby altering the optimal stimulus parameters for administering ECT. The first treatment should be initiated with standard stimulus parameters, and subsequent treatments should be adjusted accordingly.
During pregnancy, prolonged gastric emptying time increases the risk of gastric regurgitation and aspiration pneumonitis during anesthesia. The patient can be intubated to prevent these complications. However, weight gain, hypervascularity, and edema increase the likelihood that bleeding will occur during intubation (92). The increased likelihood of bleeding can be addressed by using a small (e.g., pediatric-sized) cuffed endotracheal tube, laryngoscope, and laryngoscope blade. Alternately, many anesthesiologists choose not to intubate a pregnant patient during repeated ECT treatments, but instead decrease the risk of pneumonitis by raising gastric pH by administering a nonparticulate antacid, such as sodium citrate, before the procedure (92).
Anticholinergic agents, such as atropine and glycopyrrolate, are often given to nonpregnant patients before ECT to decrease secretions and prevent bradycardia. Both of these agents decrease lower esophageal sphincter tone, increasing the risk of gastric reflux. Therefore, neither agent is recommended for routine use during pregnancy.
Intrauterine growth effects
No intrauterine growth effects have been reported.
No instances of neonatal toxicity have been described.
A few case reports have described developmental delays or mental retardation in offspring exposed to ECT in utero (89). However, neither the number nor the pattern of these reports suggests a causal relationship between ECT and the developmental delays. No systematic, long-term follow-up studies of neurobehavioral parameters have been conducted in offspring whose mothers received ECT during pregnancy.
Psychotherapies for the manic pole of bipolar disorder focus primarily on increasing adherence to treatment with medication, improving functioning in social and occupational domains, minimizing sleep deprivation (since sleep deprivation can precipitate mania ), and preventing relapse. Theoretically, improved adherence to the medication regimen and strategies to recognize and avoid triggers of manic episodes (relapse prevention) may lead to a decrease in the number of manic episodes and an increase in the length of interepisode intervals. However, little is known about the direct or indirect effect of nonpharmacological interventions on mania, and no controlled clinical trials have evaluated these strategies during pregnancy. Structured daily activities, which help minimize sleep deprivation and reduce mood lability, are particularly important during pregnancy.
Optimal treatment planning for women with bipolar disorder emphasizes overall care to promote preconception and prenatal health. Clinicians should not focus on psychotropic medication while ignoring other risk factors for poor perinatal outcome, such as obesity, smoking, and the use of alcohol or other substances of abuse. Healthy behavior, including adherence to a prenatal vitamin regimen and to a schedule of prenatal care visits, maintenance of a healthy diet, and attendance at childbirth preparation classes, must be supported.
Treatment planning is critical for minimizing the risk to the mother and fetus while limiting the morbidity from active psychiatric illness. Ideally, discussions about treatment planning should occur before the patient becomes pregnant and while the patient is euthymic. These early discussions reduce the risk for abrupt changes in therapeutic approach in the midst of an unplanned pregnancy. Informed choices coupled with close psychiatric follow-up and coordinated care with the obstetrician are the elements of an optimal model for the management of psychiatric disorders during pregnancy (9).
The most important clinical factors that influence treatment planning during pregnancy are illness history and the reproductive risks of medications. Historical factors that should be identified include the patient’s prior response to various medications, illness severity, duration of euthymia while taking medication and while not taking medication, time to relapse after medication discontinuation, and time to recover with reintroduction of pharmacotherapy.
The clinician and patient need to decide if the patient requires medication during the period before conception and during the first trimester. Stable patients may be able to discontinue taking a mood stabilizer before attempting to conceive (2, 6). Discontinuation of a maintenance pharmacologic treatment is associated with high rates of relapse, especially if discontinuation occurs abruptly, and thus the medication should be tapered slowly (94). Given the difficulty of predicting the amount of time a woman will require to conceive, a woman who discontinues medication while trying to become pregnant may be free of prophylactic treatment for many months and may be in a precarious position with regard to her risk of manic relapse. A pregravid trial of a medication taper allows the clinician and patient to assess the patient’s response and plan accordingly. Recurrence of symptoms may prompt the woman to consider the difficult choice to continue taking medication during pregnancy.
Treatment of women with severe illness presents the greatest challenge. These women are likely to continue taking medication through conception. Some women may await early documentation of pregnancy before they discontinue taking medication, and this course of action affords prophylaxis for the longest period of time up to and around the time of conception. Caution is required with some compounds, such as valproate (see earlier discussion), since teratogenic risk is greatest when exposure occurs early in pregnancy. When pregnancy is recognized, the mood stabilizer will have to be discontinued abruptly, and the abrupt discontinuation enhances the risk for illness relapse. Adjunctive (antipsychotic) medication may be used to assist in mood stabilization while medications such as valproate are tapered, but the efficacy of this approach has not been established.
Women who elect to switch their medication to an older antipsychotic or to risperidone while they are trying to conceive face other issues. These medications increase prolactin levels, thereby decreasing menstrual cyclicity and adversely affecting fertility. Since it may take several months before a woman taking these medications conceives, an agent that has less effect on prolactin may be preferable.
Patients who discontinue medication before pregnancy or during the first trimester and who remain well may or may not decide to restart medication later in the pregnancy. While the best option for some patients is to reintroduce medication only with early signs of relapse, other patients may opt to reinstitute medication regardless of whether relapse seems imminent. If the patient’s history includes self-harm, protracted recovery time, impaired insight, or evidence that her support system cannot tolerate another episode, pharmacological treatment may reduce overall risk to both mother and fetus.
For women who are required to or prefer to continue taking medication during the first trimester, it is important to emphasize that exposure to one psychotropic medication may be safer than exposure to multiple agents (95). The lowest effective dose of a medication must be used, and agents with the least teratogenic potential should be selected in preference to those that pose a higher risk. However, an agent known to be effective for a particular patient has already been proven useful in treating the disease, which may justify exposure to the drug for that patient. Older agents with case and cohort data are preferable, since drugs are not tested in pregnant women and assessment of the reproductive toxicity of a newer agent is often delayed for years after its introduction.
Second and Third Trimester
The periods of highest risk for teratogenicity are during the first trimester. However, other perinatal risks are related to later exposure. They include risks for minor malformations, behavioral effects, low birth weight, and preterm delivery. Given how little is known about these risks and about whether mood-stabilizing agents affect these risks, it is difficult to make recommendations. However, for a woman who is doing well, changing medication for the purpose of avoiding theoretical risks to potential offspring may place the woman’s current stability at risk and may not be the most prudent course.
A planned conception represents the ideal for women with bipolar disorder, but only about 50% of pregnancies are planned (88). In many instances, recognition of pregnancy will occur during or after the peak risk period for some agents. Discontinuation of the medication at that point may place the woman’s clinical well-being at risk and confer minimal benefit. The patient’s stability, week of pregnancy, psychotropic agent, and treatment preferences should be considered in adjusting the treatment plan. In addition, a higher dose of folic acid (3 mg/day) should be prescribed for the woman. Principles of streamlining medication and using the minimal effective dose can be useful treatment approaches in this scenario. Management strategies are summarized in t1.